Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARTIN T TAYLOR

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1043294481
CMS profile
228102
Location
NEW ALBANY, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$165,148.14

142 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Allergan, Inc. $89,273.82 65
Biohaven Pharmaceuticals, Inc. $35,835.74 39
AbbVie Inc. $33,757.26 26
Amgen Inc. $2,979.27 4
Lundbeck LLC $2,259.58 2
Ipsen Biopharmaceuticals, Inc $700.00 1
Kyowa Kirin, Inc. $120.00 1
ACADIA Pharmaceuticals Inc $110.69 2
Lilly USA, LLC $100.31 1
Supernus Pharmaceuticals, Inc. $11.47 1

Page 3 of 3; records 101–142 of 142 matching records. This page contains 42 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARTIN T TAYLOR

NPI 1043294481 · CMS profile ID 228102

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

NEW ALBANY, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–142 of 142 matching records. This page contains 42 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1043294481?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARTIN T TAYLOR, NPI 1043294481, CMS profile ID 228102. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–142 of 142 matching records. This page contains 42 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1043294481?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). MARTIN T TAYLOR, NPI 1043294481, CMS profile ID 228102. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–142 of 142 matching records. This page contains 42 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1043294481?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
MARTIN T TAYLOR, NPI 1043294481, CMS profile ID 228102, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–142 of 142 matching records. This page contains 42 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1043294481?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

142 matching records · $165,148.14 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 142 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–142 of 142.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Biohaven Pharmaceuticals, Inc. $13.3705/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852640265 CMS
Ipsen Biopharmaceuticals, Inc $700.0005/01/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 841913905 CMS
Supernus Pharmaceuticals, Inc. $11.4704/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845123257 CMS
Biohaven Pharmaceuticals, Inc. $1,500.0004/23/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852640261 CMS
Allergan, Inc. $750.0004/22/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792963841 CMS
Biohaven Pharmaceuticals, Inc. $500.0004/21/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852640259 CMS
Allergan, Inc. $8.3904/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792963839 CMS
Allergan, Inc. $11.8004/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792963837 CMS
Allergan, Inc. $1,800.0004/16/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792963835 CMS
Allergan, Inc. $750.0004/12/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792963833 CMS
Allergan, Inc. $15.4004/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792963829 CMS
Allergan, Inc. $4,800.0004/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792963831 CMS
Allergan, Inc. $750.0004/05/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792963827 CMS
AbbVie Inc. $1,000.0003/24/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796141285 CMS
Biohaven Pharmaceuticals, Inc. $3,000.0003/24/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852640255 CMS
Biohaven Pharmaceuticals, Inc. $124.9903/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852640257 CMS
Allergan, Inc. $25.0403/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792963823 CMS
Allergan, Inc. $750.0003/23/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792963825 CMS
Allergan, Inc. $5,400.0003/20/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792963821 CMS
Biohaven Pharmaceuticals, Inc. $500.0003/18/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852640253 CMS
Allergan, Inc. $1,800.0003/17/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792963819 CMS
Amgen Inc. $6.7203/16/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825593263 CMS
Amgen Inc. $10.0003/16/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825593267 CMS
Biohaven Pharmaceuticals, Inc. $1,500.0003/16/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852640251 CMS
Allergan, Inc. $1,800.0003/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792963817 CMS
Biohaven Pharmaceuticals, Inc. $500.0003/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852640249 CMS
Biohaven Pharmaceuticals, Inc. $500.0003/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852640247 CMS
Amgen Inc. $2,850.0003/07/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825593271 CMS
Biohaven Pharmaceuticals, Inc. $500.0003/04/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852640245 CMS
Biohaven Pharmaceuticals, Inc. $3,000.0003/03/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852640241 CMS
Biohaven Pharmaceuticals, Inc. $125.0003/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852640243 CMS
Amgen Inc. $112.5503/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825593275 CMS
Allergan, Inc. $750.0002/24/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792963815 CMS
Biohaven Pharmaceuticals, Inc. $500.0002/17/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852640239 CMS
AbbVie Inc. $1,800.0002/12/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796141283 CMS
Biohaven Pharmaceuticals, Inc. $500.0002/05/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852640237 CMS
Allergan, Inc. $14.2701/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792963813 CMS
Biohaven Pharmaceuticals, Inc. $500.0001/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852640235 CMS
Allergan, Inc. $2.0001/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792963811 CMS
Allergan, Inc. $1,750.0001/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792963809 CMS
Allergan, Inc. $600.0001/01/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792963805 CMS
Allergan, Inc. $600.0001/01/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792963807 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $133,694.35 182
PY2020 $94,160.49 108
PY2021 $165,148.14 142
PY2022 $103,973.41 109
PY2023 $73,240.72 125
PY2024 $117,613.50 134
PY2025 $133,093.32 187

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $144,272.39 144
PY2024 Principal investigator $344,546.63 185
PY2023 Principal investigator $151,698.96 37
PY2022 Principal investigator $101,197.91 26
PY2021 Principal investigator $283,273.66 32
PY2020 Principal investigator $64,350.29 12

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

144 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $811.92 12/31/2025 Non-covered Recipient Entity
THE ORTHOPEDIC FOUNDATION
A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Upper Limb Essential Tremor No dispute reported 06/30/2026 1202532422
Principal investigator 1 Ipsen Innovation $807.30 12/24/2025 Covered Recipient Teaching Hospital
St. Anns Hospital
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289884
Principal investigator 1 Ipsen Innovation $1,524.90 12/24/2025 Covered Recipient Teaching Hospital
St. Anns Hospital
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289886
Principal investigator 1 Ipsen Innovation $807.30 12/24/2025 Covered Recipient Teaching Hospital
St. Anns Hospital
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289888
Principal investigator 1 Ipsen Innovation $807.30 12/23/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288428
Principal investigator 1 Ipsen Innovation $1,524.90 12/23/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288432
Principal investigator 1 Ipsen Innovation $400.00 12/15/2025 Non-covered Recipient Entity
Orthoneuro
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288430
Principal investigator 1 Ipsen Innovation $300.00 11/27/2025 Covered Recipient Teaching Hospital
St. Anns Hospital
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289882
Principal investigator 1 Ipsen Innovation $902.20 11/24/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288420
Principal investigator 1 Ipsen Innovation $807.30 11/24/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288424
Principal investigator 1 Ipsen Innovation $807.30 11/24/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288426
Principal investigator 1 Ipsen Innovation $91.00 11/03/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288422
Principal investigator 1 Ipsen Innovation $91.00 10/31/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288398
Principal investigator 1 Ipsen Innovation $15.00 10/31/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288414
Principal investigator 1 Ipsen Innovation $2,311.40 10/27/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288388
Principal investigator 1 Ipsen Innovation $807.30 10/27/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288390
Principal investigator 1 Ipsen Innovation $1,769.30 10/27/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288396
Principal investigator 1 Ipsen Innovation $68.90 10/27/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288400
Principal investigator 1 Ipsen Innovation $807.30 10/27/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288406
Principal investigator 1 Ipsen Innovation $68.90 10/27/2025 Non-covered Recipient Entity
Orthoneuro
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288408
Principal investigator 1 Ipsen Innovation $1,769.30 10/27/2025 Non-covered Recipient Entity
Orthoneuro
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288410
Principal investigator 1 Ipsen Innovation $807.30 10/27/2025 Non-covered Recipient Entity
Orthoneuro
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288412
Principal investigator 1 Ipsen Innovation $1,900.60 10/27/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288416
Principal investigator 1 Ipsen Innovation $1,448.20 10/27/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288418
Principal investigator 1 Ipsen Innovation $91.00 10/17/2025 Covered Recipient Teaching Hospital
St. Anns Hospital
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289880
Principal investigator 1 Ipsen Innovation $35.82 10/08/2025 Non-covered Recipient Entity
Orthoneuro
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288386
Principal investigator 1 Ipsen Innovation $2,218.40 10/08/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288392
Principal investigator 1 Ipsen Innovation $71.77 10/08/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288394
Principal investigator 1 Ipsen Innovation $34.46 10/08/2025 Non-covered Recipient Entity
Orthoneuro
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288402
Principal investigator 1 Ipsen Innovation $2,218.40 10/08/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288404
Principal investigator 1 Ipsen Innovation $15.00 09/26/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288326
Principal investigator 1 Ipsen Innovation $15.00 09/26/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288328
Principal investigator 1 Ipsen Innovation $15.00 09/26/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288330
Principal investigator 1 Ipsen Innovation $15.00 09/26/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288332
Principal investigator 1 Ipsen Innovation $15.00 09/26/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288334
Principal investigator 1 Ipsen Innovation $15.00 09/26/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288336
Principal investigator 1 Ipsen Innovation $15.00 09/26/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288338
Principal investigator 1 Ipsen Innovation $15.00 09/26/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288340
Principal investigator 1 Ipsen Innovation $15.00 09/26/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288342
Principal investigator 1 Ipsen Innovation $15.00 09/26/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288346
Principal investigator 1 Ipsen Innovation $15.00 09/26/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288348
Principal investigator 1 Ipsen Innovation $15.00 09/26/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288352
Principal investigator 1 Ipsen Innovation $15.00 09/26/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288354
Principal investigator 1 Ipsen Innovation $15.00 09/26/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288356
Principal investigator 1 Ipsen Innovation $15.00 09/26/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288358
Principal investigator 1 Ipsen Innovation $15.00 09/26/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288360
Principal investigator 1 Ipsen Innovation $15.00 09/26/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288362
Principal investigator 1 Ipsen Innovation $15.00 09/26/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288364
Principal investigator 1 Ipsen Innovation $15.00 09/26/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288366
Principal investigator 1 Ipsen Innovation $30.00 09/26/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288368
Principal investigator 1 Ipsen Innovation $15.00 09/26/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288370
Principal investigator 1 Ipsen Innovation $15.00 09/26/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288372
Principal investigator 1 Ipsen Innovation $15.00 09/26/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288374
Principal investigator 1 Ipsen Innovation $15.00 09/26/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288378
Principal investigator 1 Ipsen Innovation $15.00 09/26/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288380
Principal investigator 1 Ipsen Innovation $15.00 09/26/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288382
Principal investigator 1 Ipsen Innovation $15.00 09/26/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288384
Principal investigator 1 Ipsen Innovation $400.00 09/24/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288344
Principal investigator 1 Ipsen Innovation $150.00 09/22/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288376
Principal investigator 1 Ipsen Innovation $273.00 09/12/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288350
Principal investigator 1 Ipsen Innovation $150.00 09/04/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288322
Principal investigator 1 Ipsen Innovation $150.00 09/04/2025 Non-covered Recipient Entity
Orthoneuro
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288324
Principal investigator 1 Ipsen Innovation $470.00 08/28/2025 Non-covered Recipient Entity
OrthoNeuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289078
Principal investigator 1 Ipsen Innovation $807.30 08/28/2025 Non-covered Recipient Entity
OrthoNeuro
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289080
Principal investigator 1 Ipsen Innovation $50.00 07/30/2025 Non-covered Recipient Entity
Orthoneuro
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288282
Principal investigator 1 Ipsen Innovation $300.00 07/30/2025 Non-covered Recipient Entity
Orthoneuro
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288284
Principal investigator 1 Ipsen Innovation $1,376.70 07/30/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288296
Principal investigator 1 Ipsen Innovation $807.30 07/28/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288302
Principal investigator 1 Ipsen Innovation $807.30 07/28/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288310
Principal investigator 1 Ipsen Innovation $150.00 07/25/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288312
Principal investigator 1 Ipsen Innovation $300.00 07/25/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288314
Principal investigator 1 Ipsen Innovation $91.00 07/23/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288278
Principal investigator 1 Ipsen Innovation $91.00 07/23/2025 Non-covered Recipient Entity
Orthoneuro
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288286
Principal investigator 1 Ipsen Innovation $150.00 07/23/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288288
Principal investigator 1 Ipsen Innovation $20.38 07/23/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288294
Principal investigator 1 Ipsen Innovation $150.00 07/23/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288298
Principal investigator 1 Ipsen Innovation $350.00 07/23/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288300
Principal investigator 1 Ipsen Innovation $300.00 07/23/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288308
Principal investigator 1 Ipsen Innovation $90.00 07/16/2025 Non-covered Recipient Entity
Orthoneuro
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288318
Principal investigator 1 Ipsen Innovation $450.00 07/16/2025 Non-covered Recipient Entity
Orthoneuro
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288320
Principal investigator 1 Ipsen Innovation $1,900.00 07/04/2025 Non-covered Recipient Entity
Orthoneuro
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288280
Principal investigator 1 Ipsen Innovation $2,218.40 07/04/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288290
Principal investigator 1 Ipsen Innovation $85.23 07/04/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288292
Principal investigator 1 Ipsen Innovation $2,168.40 07/04/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288304
Principal investigator 1 Ipsen Innovation $2,168.40 07/04/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288306
Principal investigator 1 Ipsen Innovation $700.00 07/03/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288316
Principal investigator 1 Ipsen Innovation $807.30 06/30/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288242
Principal investigator 1 Ipsen Innovation $807.30 06/30/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288244
Principal investigator 1 Ipsen Innovation $1,336.40 06/30/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288246
Principal investigator 1 Ipsen Innovation $807.30 06/30/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288248
Principal investigator 1 Ipsen Innovation $830.70 06/30/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288250
Principal investigator 1 Ipsen Innovation $68.90 06/30/2025 Non-covered Recipient Entity
Orthoneuro
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288254
Principal investigator 1 Ipsen Innovation $807.30 06/30/2025 Non-covered Recipient Entity
Orthoneuro
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288256
Principal investigator 1 Ipsen Innovation $830.70 06/30/2025 Non-covered Recipient Entity
Orthoneuro
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288258
Principal investigator 1 Ipsen Innovation $1,336.40 06/30/2025 Non-covered Recipient Entity
Orthoneuro
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288260
Principal investigator 1 Ipsen Innovation $1,376.70 06/30/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288262
Principal investigator 1 Ipsen Innovation $1,453.40 06/30/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288264
Principal investigator 1 Ipsen Innovation $68.90 06/30/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288266
Principal investigator 1 Ipsen Innovation $807.30 06/30/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288268
Principal investigator 1 Ipsen Innovation $1,453.40 06/30/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288270
Principal investigator 1 Ipsen Innovation $807.30 06/30/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288272
Principal investigator 1 Ipsen Innovation $807.30 06/30/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288274
Principal investigator 1 Ipsen Innovation $807.30 06/30/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288276
Principal investigator 1 Ipsen Innovation $69.31 06/25/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288252
Principal investigator 1 Ipsen Innovation $90.00 05/29/2025 Non-covered Recipient Entity
Orthoneuro
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288236
Principal investigator 1 Ipsen Innovation $450.00 05/29/2025 Non-covered Recipient Entity
Orthoneuro
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288238
Principal investigator 1 Ipsen Innovation $300.00 05/21/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288240
Principal investigator 1 Ipsen Innovation $2,168.40 04/28/2025 Non-covered Recipient Entity
OrthoNeuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289024
Principal investigator 1 Ipsen Innovation $1,829.10 04/28/2025 Non-covered Recipient Entity
OrthoNeuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289026
Principal investigator 1 Ipsen Innovation $68.90 04/28/2025 Non-covered Recipient Entity
OrthoNeuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289028
Principal investigator 1 Ipsen Innovation $807.30 04/28/2025 Non-covered Recipient Entity
OrthoNeuro
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289040
Principal investigator 1 Ipsen Innovation $1,697.80 04/28/2025 Non-covered Recipient Entity
OrthoNeuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289044
Principal investigator 1 Ipsen Innovation $1,829.10 04/28/2025 Non-covered Recipient Entity
OrthoNeuro
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289046
Principal investigator 1 Ipsen Innovation $807.30 04/28/2025 Non-covered Recipient Entity
OrthoNeuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289048
Principal investigator 1 Ipsen Innovation $807.30 04/28/2025 Non-covered Recipient Entity
OrthoNeuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289050
Principal investigator 1 Ipsen Innovation $807.30 04/28/2025 Non-covered Recipient Entity
OrthoNeuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289052
Principal investigator 1 Ipsen Innovation $68.90 04/28/2025 Non-covered Recipient Entity
OrthoNeuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289054
Principal investigator 1 Ipsen Innovation $68.90 04/28/2025 Non-covered Recipient Entity
OrthoNeuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289056
Principal investigator 1 Ipsen Innovation $68.90 04/28/2025 Non-covered Recipient Entity
OrthoNeuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289058
Principal investigator 1 Ipsen Innovation $68.90 04/28/2025 Non-covered Recipient Entity
OrthoNeuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289060
Principal investigator 1 Ipsen Innovation $807.30 04/28/2025 Non-covered Recipient Entity
OrthoNeuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289062
Principal investigator 1 Ipsen Innovation $807.30 04/28/2025 Non-covered Recipient Entity
OrthoNeuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289064
Principal investigator 1 Ipsen Innovation $1,697.80 04/28/2025 Non-covered Recipient Entity
OrthoNeuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289066
Principal investigator 1 Ipsen Innovation $807.30 04/28/2025 Non-covered Recipient Entity
OrthoNeuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289068
Principal investigator 1 Ipsen Innovation $1,453.40 04/28/2025 Non-covered Recipient Entity
OrthoNeuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289070
Principal investigator 1 Ipsen Innovation $1,376.70 04/28/2025 Non-covered Recipient Entity
OrthoNeuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289072
Principal investigator 1 Ipsen Innovation $807.30 04/28/2025 Non-covered Recipient Entity
OrthoNeuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289074
Principal investigator 1 Ipsen Innovation $68.90 04/28/2025 Non-covered Recipient Entity
OrthoNeuro
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289076
Principal investigator 1 Ipsen Innovation $450.00 04/17/2025 Non-covered Recipient Entity
OrthoNeuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289030
Principal investigator 1 Ipsen Innovation $360.00 04/17/2025 Non-covered Recipient Entity
OrthoNeuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289032
Principal investigator 1 Ipsen Innovation $90.00 04/16/2025 Non-covered Recipient Entity
OrthoNeuro
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289034
Principal investigator 1 Ipsen Innovation $150.00 04/16/2025 Non-covered Recipient Entity
OrthoNeuro
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289036
Principal investigator 1 Ipsen Innovation $300.00 04/01/2025 Non-covered Recipient Entity
OrthoNeuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289038
Principal investigator 1 Ipsen Innovation $300.00 04/01/2025 Non-covered Recipient Entity
OrthoNeuro
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289042
Principal investigator 1 ABBVIE INC. $4,271.10 03/06/2025 Non-covered Recipient Entity
THE ORTHOPEDIC FOUNDATION
M21-471 - Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor No dispute reported 06/30/2026 1202457507
Principal investigator 1 ABBVIE INC. $975.00 02/26/2025 Non-covered Recipient Entity
THE ORTHOPEDIC FOUNDATION
M21-471 - Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor No dispute reported 06/30/2026 1202453926
Principal investigator 1 ABBVIE INC. $2,500.00 02/13/2025 Non-covered Recipient Entity
THE ORTHOPEDIC FOUNDATION
M21-471 - Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor No dispute reported 06/30/2026 1202451009
Principal investigator 1 ABBVIE INC. $67.00 02/06/2025 Non-covered Recipient Entity
THE ORTHOPEDIC FOUNDATION
M21-471 - Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor No dispute reported 06/30/2026 1202447246
Principal investigator 1 ABBVIE INC. $21,869.80 02/05/2025 Non-covered Recipient Entity
THE ORTHOPEDIC FOUNDATION
M21-471 - Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor No dispute reported 06/30/2026 1202444142
Principal investigator 1 ABBVIE INC. $21,288.00 02/05/2025 Non-covered Recipient Entity
THE ORTHOPEDIC FOUNDATION
M21-471 - Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor No dispute reported 06/30/2026 1202444145
Principal investigator 1 ABBVIE INC. $8,446.90 02/05/2025 Non-covered Recipient Entity
THE ORTHOPEDIC FOUNDATION
M21-471 - Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor No dispute reported 06/30/2026 1202444187
Principal investigator 1 ABBVIE INC. $3,612.80 02/05/2025 Non-covered Recipient Entity
THE ORTHOPEDIC FOUNDATION
M21-471 - Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor No dispute reported 06/30/2026 1202444191
Principal investigator 1 Ipsen Innovation $807.30 01/27/2025 Non-covered Recipient Entity
Orthoneuro
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288234
Principal investigator 1 ABBVIE INC. $67.00 01/16/2025 Non-covered Recipient Entity
THE ORTHOPEDIC FOUNDATION
M21-471 - Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor No dispute reported 06/30/2026 1202439123